Charged 2026

Author: Alexandra Marshall

  • Organoids Part Two: Despite Limitations, They’re Still Amazing

    Clearly one article wasn’t enough to explore the full potential of organoids, so here we go again. This article won’t make much sense without reading the first but a quick catch up:
    Organoids are 3D cell structures grown from Stem cell samples and grown in nutrient rich gel.

    • They can better model human systems as they are more complex than their 2D counterparts and a better representation of human systems than animal models.
    • This advantage makes organoids uniquely beneficial to the field of drug research and testing and personalized medicine.
    • Link to original article if desired: https://2026.chargedmag.org/2026/04/organoids-what-are-they-and-why-theyre-amazing/

    Limitations
    These applications are not without limitations however. While organoids can replicate many aspects of human tissue, some specific cell genes are harder to find in organoids (Andrews and Kriegstein, 2022). This impaired the organoids’ ability to properly simulate the systems they are derived from, preventing researchers from properly modeling diseases and treatments in that area.

    Additionally, while developments have been made to improve organoid lifespans, organoids still require controlled environments and regular care to survive (Simian and Bissell, 2016). Even the longest lasting organoids, neurological models, have only survived a couple of years. Many organoids will even grow patches of dead tissue in the center due to a lack of oxygen hindering their research capabilities (Andrews & Kriegstein, 2022). In organic systems, cells are constantly interchanging molecules to maintain their functions and prevent necrosis. The nutritional gel can only do so much to get the molecules to cells at the interior of organoid structure without the natural systems to supply it.

    All of this causes organoid maintenance to be costly compared to in-vitro models, which are relatively cheap and easy to handle (Schutgens & Clevers, 2020). This stifles research leading to many knowledge gaps in the field. Furthermore, these restrictions limit modeling larger systems. Potential treatments tested in smaller organoids could have unpredictable impacts on a larger system when prescribed. Concerns around this limits applications of organoids, creating Theory-Application Voids.

    There are also many population gaps in organoid research as certain demographics are underrepresented in the stem cells used to create the organoids. These stem cells are often pulled from stem cell donor registries which have significant demographic, systemic, and behavioral biases. Further development into organoids and increased diversity in biobanks can increase organoid capabilities and applications.

    Concerns
    There are also current concerns surrounding organoid research that need to be addressed. While organoid models no longer rely on stem cells taken from embryos, they are still used in organoids modeling traditional embryo frameworks. These models use STEM cells to study the process of early embryonic development and can be very useful in identifying gestation concerns or potential risks to a fetus (Pereira et al., 2020). Once again, the line of when a zygote becomes a person however, gets blurry. Multiple public figures and many private citizens are debating if the creation of an embryo, even as a limited organoid, for study is ethical.

    There are also concerns about neurological organoid models used for neurological diseases (Lavazza and Massimini, 2018). Current models can only imitate parts of the human brain. However, as models more closely resemble a human brain with increased functionality, ethical questions surrounding the creation and experimentation of something than can think and feel will only grow. The line being living, sentient, and sapient is hard to discern, especially with limited structures that might not have the ability to communicate mental facilities.

    Future implementations of organoid models also raise ethical concerns regarding their financial exploitation and patient consent. People’s cell matter must be collected and added to databases to be used in organoid research (Bredenoord et al., 2017). Active patient involvement in organoid development is essential when considering this process. Their participation in cell donation must remain voluntary and properly compensated, and this is currently not guaranteed.

    The implementation of organoids in personalized medicine could also have complications on the healthcare system (Stefanicka-Wojtas & Kurpas, 2023). While organoids could improve personalized medicine, the increased specificity of treatments could lead to decreased procedure lifespans and certainty. The underrepresentation and price of organoid backed research could also exacerbate existing disparities in healthcare and lead to an increase in general healthcare costs or dropped plans due to cost-shifting (What’s Behind Rising Health Insurance Costs? | Johns Hopkins Bloomberg School of Public Health, 2025).

    Scientists in organoid research have repeatedly advocated for remaining cautious and careful in this relatively unexplored ethical field.

    Potential Applications
    Despite all of that dour news, organoids are still having a positive impact on millions of people with the potential to aid millions more. Unfortunately we only have time for two of these here: Regenerative Medicine and Transplantation.

    Regenerative Medicine is the field of science dedicated to the regeneration and restoration of human tissue based in Stem cells. Many different animals have regenerative properties from the regrowth and axolotl limbs to sea cucumbers regrowing internal organs to flatworms regrowing entire heads. Throughout history scientists have been inspired by these properties and researched the mechanisms behind them, leading to the field of regenerative medicine. While the study of artificial organs has been around since the 1930s, the modern idea of regenerative medicine centered around Stem cells started in the 1990s (Sampogna et al., 2015).

    As mentioned in my first article, the very purpose of Stem cells is to replace damaged, specialized cells. By comprehending the properties behind their functions, scientists can apply them to other areas. It is organoids that allow scientists to grow the cell cultures and tissue samples that are behind regenerative research. If someone has a large wound or damaged organ, an organoid of that structure could be applied and integrated into the person’s natural system. The organoid could be made from the person’s own cells, bypassing an immune response that comes with many non-biomaterials or transplants. This has already been proven promising. In one study, organoids made from the stem cells of mice suffering from inflammation and damage of their colon lining were successfully transferred onto the mice’s injured tissue. The cultured tissue covered the damage leading to a decrease in inflammation and harmful symptoms (Babak Arjmand et al., 2022). There are currently limitations, such as the delivery of nutrients mentioned above that directly challenge this field, but with more research scientists can find better ways for organoids to improve people’s lives through regenerative medicine.

    Transplantation is a great example of the applications of regenerative medicine. As mentioned above, tissues and cell cultures can be grown using organoids. This is not the extent of their potential however. As organoid research develops, scientists are working to make larger and more complex models. Through assembloids, the combinations of different types of organoid (a topic for a later article), lab made organs or entire organ systems could be created from a single stem cell. In 2025, scientists were able to successfully transplant pig kidneys made from organoids (SMC Spain, 2025). In the future organoids could be used to transplant an entire human heart or cardiovascular system. An even farther yet still plausible possibility would be the creation of entire limbs for transplants with scientists already researching limb organoids (Tsutsumi & Mototsugu Eiraku, 2023). Approximately 5,600 people in the U.S. die each year simply waiting for a transplant in addition to the 30% of recipients who die within 10 years of a transplant due to complications such as transplant rejection (What Are the Complications of Transplantation?, 2019). Organoids have the potential to prevent these deaths, and while there are still complications due to the price and longevity of organoids, they will only improve with continued exploration.

    Conclusion
    Organoids are amazing. They have the ability to impact almost every field of biomedical science and save millions of lives. While this article does take a much more nuanced look at organoids, diving into their limitations and complications, scientists are aware of these issues and taking careful approaches to research. Improvements in organoids, especially to their limitations, can only be made if research is supported and continued. There is still so much potential for organoids that we have only just scratched the surface of and so many more applications that we haven’t even considered yet. Organoids have even been proven to work with many other biomedical instruments and tools, aiding in their development as well. The possibilities are endless.

    Organoids are my passion, I’ve been interested in them for years now. Yet no one knew what I was going on and on about. I hope that these articles inspire curiosity and spread the wonders of organoids to others.

    ————————————————————————————————

    Works Cited:

    Title Image: Illustration created by Alexandra Marshall

    Andrews, M. G., & Kriegstein, A. R. (2022). Challenges of Organoid Research. Annual Review of Neuroscience, 45(1), 23–39. https://doi.org/10.1146/annurev-neuro-111020-090812

    Babak Arjmand, Rabbani, Z., Faezeh Soveyzi, Akram Tayanloo-Beik, Mostafa Rezaei-Tavirani, Mahmood Biglar, Adibi, H., & Bagher Larijani. (2022). Advancement of Organoid Technology in Regenerative Medicine. Regenerative Engineering and Translational Medicine, 9(1), 83–96. https://doi.org/10.1007/s40883-022-00271-0

    Bredenoord, A. L., Clevers, H., & Knoblich, J. A. (2017). Human tissues in a dish: The research and ethical implications of organoid technology. Science, 355(6322). https://doi.org/10.1126/science.aaf9414

    Lavazza, A., & Massimini, M. (2018). Cerebral organoids: ethical issues and consciousness assessment. Journal of Medical Ethics, 44(9), 606–610. https://doi.org/10.1136/medethics-2017-104555

    Pereira, A. M., Popovic, M., Dondorp, W. J., Bustos, M. T., Bredenoord, A. L., Chuva, S. M., Susanne, Roelen, B. A. J., Guido, & Björn Heindryckx. (2020). Modelling human embryogenesis: embryo-like structures spark ethical and policy debate. Human Reproduction Update, 26(6), 779–798. https://doi.org/10.1093/humupd/dmaa027

    Sampogna, G., Guraya, S. Y., & Forgione, A. (2015). Regenerative medicine: Historical roots and potential strategies in modern medicine. Journal of Microscopy and Ultrastructure, 3(3), 101–107. https://doi.org/10.1016/j.jmau.2015.05.002

    Spain, S. (2025, October 31). For the first time, pig kidneys modified with human renal organoids are transplanted into pigs. SMC España. https://sciencemediacentre.es/en/first-time-pig-kidneys-modified-human-renal-organoids-are-transplanted-pigs#:~:text=Pig%20kidneys%20modified%20with%20human%20renal%20organoids

    Schutgens, F., & Clevers, H. (2020). Human Organoids: Tools for Understanding Biology and Treating Diseases. Annual Review of Pathology: Mechanisms of Disease, 15(1), 211–234. https://doi.org/10.1146/annurev-pathmechdis-012419-032611

    Simian, M., & Bissell, M. J. (2016). Organoids: A historical perspective of thinking in three dimensions. The Journal of Cell Biology, 216(1), 31–40. https://doi.org/10.1083/jcb.201610056

    Stefanicka-Wojtas, D., & Kurpas, D. (2023). Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions). Journal of Personalized Medicine, 13(3), 380. https://doi.org/10.3390/jpm13030380

    Tsutsumi, R., & Mototsugu Eiraku. (2023). How might we build limbs in vitro informed by the modular aspects and tissue-dependency in limb development? Frontiers in Cell and Developmental Biology, 11, 1135784–1135784. https://doi.org/10.3389/fcell.2023.1135784

    What are the complications of transplantation? (2019, April). National Kidney Federation. https://www.kidney.org.uk/what-are-the-complications-of-transplantation#:~:text=Within%20one%20year%20of%20any,ten%20years%20after%20a%20transplant.

     

  • Organoids: What are They and Why They’re Amazing

    I’m willing to bet you’ve never heard of Organoids. No worries if so, they’re a pretty niche part of biomedical sciences. This is such a shame however as they’re having a great impact on research and our world. Organoids are often defined as tissue samples embedded into 3D extracellular matrix (ECM) gels or clonal derivatives of cells grown without mesenchyme and derived from stem cells. Don’t worry if your eyes have already glazed over! Mine did too the first time I read that.

    In simpler terms, they are the growing of cells, taken from a patient, in a nutrient rich gel. While the field might seem niche at first, it has a long history and the potential to impact millions.

    Before Organoids, most human physiological research relied on in vitro 2D cell culture and animal models (O’Connell & Winter, 2019). These often fail at clinical trials due to oversimplification of or incompatibility with human systems. At the time, cell cultures were limited to growing single layers of cells in a petri dish with none of the 3D complexities of real biological systems. This all changed with Ross Harrison’s “Hanging drop Cell Cultures” in 1906 (Simian and Bissell, 2016). By creating a 2D cell culture and turning the petri dish upside down, gravity would cause the cells to clump together and form a cohesive 3D spheroid of cells that could intermingle and interact like normal. Think about that! 3D structures could form by simply turning them upside down with no other interference. This was the start of research into organoids which offered a new way to look directly at human biology without risking patient or animal lives.

    One key breakthrough was the discovery of 3D extracellular matrices first used in 1963 (Simian and Bissell, 2016). The gel provided a medium for natural scaffolding of cells rather than relying on gravity. This allowed for more complex 3D shapes and allowed for more types of organoids that more closely resembled complex real life systems. The gel also aided in providing the cells with nutrients required to keep them alive. Hence the “nutrient rich gel” from the definition above.

    Exploration into this new field was rather slow however. The human body is composed of roughly 200 distinct types of cells, each of which specialize in a different function such as blood or nerve cells. Despite this, organoids mainly rely on only two types of cells, pluripotent stem cells and organ-restricted adult stem cells (Bredenoord et al., 2017). Stem cells are unspecified types of cells, yet to differentiate, with the ability to become any type of specified cell. They often serve to repair the human body as they can replace any damaged cells no matter the type. This ability makes them highly valuable to organoids trying to model systems that rely on the cooperation of multiple cell types.

    Before the discovery of induced stem cells in 2006 by Dr. Shinya Yamanaka at Kyoto University, organoids were made from pluripotent stem cells as organ-restricted adult stem cells can be hard to access and are restricted to becoming cell types of their tissue of origin most commonly found in embryos (Agarwal et al., 2024). The line of when a zygote becomes a person, however, is blurry, raising many ethical concerns about the desecration of a person’s body. Induced stem cells allow for the change of specialized cells back into stem cells. Organoids can now be created from any tissue sample, entirely limiting the need for embryonic stem cells outside of studying early organ development (Frans Schutgens & Clevers, 2019).

    With better ways to develop organoids, scientists quickly realized their potential. Organoids offer unparalleled advancement in disease research and treatment, personalized medicine, and so much more that we simply don’t have time for here.

    Image by Alexandra Marshall

    Disease Research and Treatment
    One pivotal area of applications is understanding the development of diseases and disease treatment in humans. The lack of 3D structure in in vitro models lead to limited complexity and physiological relevance when studying diseases. Faulty predictions based on these studies can lead to treatments failing, with approximately 90% of clinical study drug candidates failing clinical trials and drug approval (Sun et al., 2022).

    Organoid models have none of these limitations. In 2013, the first human condition modeled using organoids, cystic fibrosis, was published. The model had “excellent predictive value” and became the first successful personalized treatment method for cystic fibrosis patients (Lancaster and Huch, 2019). The modeling of other diseases using organoids quickly followed from genetic diseases like Polycystic kidney disease and Alagille syndrome, to infectious diseases like Covid-19 and the Zika virus, to neurological diseases like Alzheimer’s and Parkinson’s, to multitudes of cancers, and more (Xu et al., 2018). The ability for organoids to be made of any human system means they can model any disease regardless of which systems they afflict.

    Organoids can be also grown co-culturally with bacteria allowing for bacterial infections and the diseases that arise from them to also be modeled and researched with organoids (Schutgens and Clevers, 2020). This has allowed for better understanding of bacteria like Helicobacter Pylori and Salmonella, aiding in detection and cures. As mentioned above, treatments can then be tested on these organoid systems without risking human lives or animal cruelty.

    Respiratory Syncytial Virus (RSV), a disease that is being modeled in airway organoids, causes around 66,000–199,000 deaths among children annually (Schutgens & Clevers, 2020). This is just one of the many diseases for which scientists are now better equipped to find viable treatments. Organoids have already saved millions of lives and their potential for future disease treatment has the potential to millions more.

    Personalized Medicine
    While these treatments work for many people, genetic and biological differences can impact treatment effectiveness and tolerance with some even leading to negative side effects (Breen, 2021). In such situations, personalized medicine that is specialized to fit these differences might be necessary. Personalized medicine, sometimes called precision medicine, challenges the idea that treatments that pass general trials will work for everyone, instead working to construct a treatment plan with a specific patient in mind best suited to their physiology.

    The idea of personalized medicine has been around for thousands of years, using one’s family’s history of diseases to diagnose the likelihood of that person having said disease. In the late 1900s the idea of evidence based medicine, the implementation of explicit reasoning based on a specific patient’s data, started being common practice when prescribing a patient (Visvikis-Siest et al., 2020). This opened the door for personalized medicine in modern science (Visvikis-Siest et al., 2020). This data was largely based on patients’ reactions to other treatments and family history however limited its effectiveness. The development of molecular biology and human genome mapping allows for a direct look at a patient’s physiology, aiding medical professionals in determining the biological reasons behind potential reactions to treatments before administration limiting adverse reactions.

    Organoids have greatly furthered this field. As mentioned above, organoids are made from a patient’s induced stem cells. This means that the organoid culture into a structure based on the patient’s DNA, containing all the same biomarkers and physiology that the patient would have at that level. Where other treatments could have varying effects from the tested population, organoids allow medical professionals to see the exact effects a treatment plan would have on the patient. The use of stem cells also allows organoids to grow much quicker than other models. This allows for quick and accurate testing of the effects of medication on a patient. One study published in Science involving gastrointestinal cancer therapies found that organoids would correctly detect when drugs would fail 100% of the time, and when the drug would succeed 88% percent of the time (Vlachogiannis et al., 2018). Once again, because of the diversity of systems that organoids can model, organoids can be used to model many different personalized medicine plans allowing for the variety of treatment testing needed to find the most optimal plan.

    Conclusion
    Organoids have had a monumental, yet widely unknown, impact on a wide variety of disease advancement and treatment developments and personalized medicine. These structures can then be used to model human tissues and organs with much higher accuracy and complexity than previously used non-human or in vitro models.

    Scientists use them to model disease development in humans and treatments designed for humans. This allows for a better understanding of the diseases and more effective treatments with fewer errors. They are also used to limit the risk of negative side effects from non-personalized medicine by furthering personalized medicine through the accuracy and speedy testing of many different treatment options.
    With continued and careful development of organoids, disease understanding and treatments, personalized medicine and so much more can continue to be improved, saving millions of lives.

    ————————————————————————————————-

    Work Cited:
    Agarwal, S., Saha, L., Sohani, A., Karri, U., Gor, R., & Ramalingam, S. (2024). The importance of niche in therapeutic strategies targeting normal and cancer stem cells. Cancer Stem Cells and Signaling Pathways, 15–33. https://doi.org/10.1016/b978-0-443-13212-4.00031-3

    Bredenoord, A. L., Clevers, H., & Knoblich, J. A. (2017). Human tissues in a dish: The research and ethical implications of organoid technology. Science, 355(6322). https://doi.org/10.1126/science.aaf9414

    Frans Schutgens, & Clevers, H. (2019). Human Organoids: Tools for Understanding Biology and Treating Diseases. Annual Review of Pathology Mechanisms of Disease, 15(1), 211–234. https://doi.org/10.1146/annurev-pathmechdis-012419-032611

    Generation and Cultivation of 3D Cell Models | ibidi. (2024). Ibidi. https://ibidi.com/content/1037-generation-and-cultivation-of-3d-cell-models

    Lancaster, M. A., & Huch, M. (2019). Disease modelling in human organoids. Disease Models & Mechanisms, 12(7). https://doi.org/10.1242/dmm.039347

    O’Connell, L., & Winter, D. C. (2019). Organoids: Past Learning and Future Directions. Stem Cells and Development, 29(5), 281–289.https://doi.org/10.1089/scd.2019.0227

    Schutgens, F., & Clevers, H. (2020). Human Organoids: Tools for Understanding Biology and Treating Diseases. Annual Review of Pathology: Mechanisms of Disease, 15(1), 211–234. https://doi.org/10.1146/annurev-pathmechdis-012419-032611

    ‌Simian, M., & Bissell, M. J. (2016). Organoids: A historical perspective of thinking in three dimensions. The Journal of Cell Biology, 216(1), 31–40. https://doi.org/10.1083/jcb.201610056

    Sun, D., Gao, W., Hu, H., & Zhou, S. (2022). Why 90% of clinical drug development fails and how to improve it? Acta Pharmaceutica Sinica B, 12(7), 3049–3062. https://doi.org/10.1016/j.apsb.2022.02.002

    Visvikis-Siest, S., Theodoridou, D., Kontoe, M.-S., Kumar, S., & Marschler, M. (2020). Milestones in Personalized Medicine: From the Ancient Time to Nowadays—the Provocation of COVID-19. Frontiers in Genetics, 11. https://doi.org/10.3389/fgene.2020.569175

    Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., Rata, M., Koh, D.-M., Tunariu, N., Collins, D., Hulkki-Wilson, S., Ragulan, C., Spiteri, I., Moorcraft, S. Y., Chau, I., & Rao, S. (2018). Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 359(6378), 920–926. https://doi.org/10.1126/science.aao2774

    Xu, H., Jiao, Y., Qin, S., Zhao, W., Chu, Q., & Wu, K. (2018). Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine. Experimental Hematology and Oncology, 7(1). https://doi.org/10.1186/s40164-018-0122-9